Ipamorelin Doses, As the Studies Administered Them

Read this first

This page lists doses that appear in published ipamorelin studies. It does not tell anyone what to take. There is no approved human dose, because the compound was never approved ^[3].

The numbers below are reported as the researchers used them: which species, which route (into a vein, under the skin, into the belly), how much, how often, for how long. A dose that was given to a rat, or to a patient in a trial, is not a recommendation for anyone.

Two facts orient the rest. The half-life in humans is about 2 hours, and the GH response is a single pulse peaking near 40 minutes ^[2]. And the popular subcutaneous "stack" protocols people share online have no controlled human dosing basis — they are community practice, described here as anecdote, not endorsed.

Doses used in the studies

Human, IV (pharmacology): five 15-minute IV infusions across 4.21–140.45 nmol/kg, single doses, n=8 per level ^[2].

Human, IV (Phase 2 trial): 0.03 mg/kg IV twice daily, postoperative days 1–7 or until discharge, n=114 — the regimen that missed its endpoint ^[3].

Rat, subcutaneous (bone growth): 18, 90, 450 microgram/day, divided three times daily, 15 days ^[4].

Rat, IV (under steroid load): 0.4–1.6 mg/kg/day, four times daily, alongside methylprednisolone ^[11].

Ferret, intraperitoneal (cachexia model): 1–3 mg/kg ^[5].

These are not interchangeable across species, and none translates to a human protocol. They are the doses the literature actually used.

Half-life and kinetics

Terminal half-life in healthy human volunteers is about 2 hours (IV), with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg ^[2]. The GH response is a single discrete pulse peaking near 40 minutes after dosing ^[2]. In rats, plasma clearance runs roughly 5-fold lower than GHRP-6.

Kinetics are dose-proportional across the studied range ^[2] — linear pharmacology, a short window of action, and a self-limiting GH pulse rather than a sustained elevation.

Routes studied

Ipamorelin has been administered intravenously (human PK and the clinical trial; rodent efficacy), subcutaneously (rodent bone and body-composition work, and the dominant route in community use), intranasally (rodent PK, ~20% bioavailability), and intraperitoneally (rodent and ferret efficacy) ^[4][5].

Oral does not work for ipamorelin itself — only engineered ipamorelin-derived analogs reached oral bioavailability (NN703 ~30% in dog; a peptidomimetic series ~10%) ^[8]. Ipamorelin as such is not orally bioavailable.

How much cjc-1295 ipamorelin should i take

There is no answer this site will give, because none is established. How much cjc-1295 ipamorelin should i take has no controlled human dosing basis: the combination was never tested as a product in a human trial, and ipamorelin has no approved dose for any use ^[3]. The subcutaneous "stack" regimens circulated in forums are community practice — anecdotal, unverified, and not a recommendation. The only human dosing on record for ipamorelin alone is IV and from research settings ^[2][3], neither of which is a personal protocol.

How to reconstitute cjc-1295 ipamorelin 5mg

How to reconstitute cjc-1295 ipamorelin 5mg is a research-handling question, not a clinical instruction, and this site gives no preparation protocol. As context only: ipamorelin is supplied as a lyophilized (freeze-dried) powder, free base or acetate salt, and the research-supply literature describes reconstitution with bacteriostatic water for handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is generally kept refrigerated. These are general peptide-handling observations from the research-supply literature — not a clinical preparation method, not a dose, and not advice.